Precision BioSciences doses first patient in DMD gene-editing trial
The company said the first patient received PBGENE-DMD at Arkansas Children's Hospital in August 2026, with initial safety data expected by year-end.
SEC filing
Latest
3 stories
Monday, August 24
Thursday, August 6
Precision BioSciences reports first biopsy evidence of cccDNA elimination in HBV trial
Q2 2026 update shows liver biopsy proof of viral DNA reduction and sustained pgRNA loss in the ELIMINATE-B trial, as DMD trial sites begin recruiting.
SEC filing
Monday, July 27
Precision BioSciences promotes CFO to COO, names new CFO effective August 1
The Board approved the executive changes on July 23, 2026, and the company announced them in a press release on July 27, 2026.
SEC filing